AMEX: ASXC | Healthcare / Medical Devices & Instruments / USA |
0.2620 | +0.0005 | +0.19% | Vol 759.07K | 1Y Perf -43.15% |
Oct 4th, 2023 16:00 DELAYED |
BID | 0.2610 | ASK | 0.2698 | ||
Open | 0.2600 | Previous Close | 0.2615 | ||
Pre-Market | - | After-Market | 0.26 | ||
- - | -0.01 -2.29% |
Target Price | 2.25 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 758.78 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -100/71/71 | Value Ranking | ★★★★ 55.01 | |
Insiders Value % 3/6/12 mo. | -100/89/89 | Growth Ranking | ★★★ 50.55 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/83/83 | Income Ranking | — - | |
Price Range Ratio 52W % | 1.25 | Earnings Rating | — | |
Market Cap | 69.14M | Earnings Date | 9th Nov 2023 | |
Alpha | -0.03 | Standard Deviation | 0.56 | |
Beta | 1.62 |
Today's Price Range 0.26000.2696 | 52W Range 0.25041.18 | 5 Year PE Ratio Range -1.30-0.3000 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -5.76% | ||
1 Month | -12.67% | ||
3 Months | -43.86% | ||
6 Months | -57.74% | ||
1 Year | -43.15% | ||
3 Years | -24.28% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -45.50 | |||
ROE last 12 Months | -55.15 | |||
ROA (5Y Avg) | -28.37 | |||
ROA last 12 Months | -49.38 | |||
ROC (5Y Avg) | -72.06 | |||
ROC last 12 Months | -48.50 | |||
Return on invested Capital Q | -14.94 | |||
Return on invested Capital Y | -8.82 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.50 | ||||
0.98 | ||||
23.22 | ||||
- | ||||
-2.40 | ||||
-0.25 | ||||
0.99 | ||||
0.48 | ||||
29.55M | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.10 | ||||
10.50 | ||||
0.04 | ||||
0.05 | ||||
-98.70 | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-53.00 | ||||
-1 019.40 | ||||
-832.80 | ||||
-1 349.00 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.62M | ||||
0.02 | ||||
-24.29 | ||||
-0.29 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.08 | -0.09 | -12.50 |
Q01 2023 | -0.07 | -0.09 | -28.57 |
Q04 2022 | -0.07 | -0.07 | 0.00 |
Q03 2022 | -0.07 | -0.07 | 0.00 |
Q02 2022 | -0.08 | -0.07 | 12.50 |
Q01 2022 | -0.08 | -0.07 | 12.50 |
Q04 2021 | -0.07 | -0.07 | 0.00 |
Q03 2021 | -0.06 | -0.06 | 0.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | 9th Nov 2023 |
Estimated EPS Next Report | -0.07 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 759.07K |
Shares Outstanding | 263.87K |
Shares Float | 259.32M |
Trades Count | 1.38K |
Dollar Volume | 200.48K |
Avg. Volume | 2.88M |
Avg. Weekly Volume | 1.26M |
Avg. Monthly Volume | 4.53M |
Avg. Quarterly Volume | 2.85M |
Asensus Surgical Inc. (AMEX: ASXC) stock closed at 0.262 per share at the end of the most recent trading day (a 0.19% change compared to the prior day closing price) with a volume of 759.07K shares and market capitalization of 69.13M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 138 people. Asensus Surgical Inc. CEO is Anthony C. J. Fernando.
The one-year performance of Asensus Surgical Inc. stock is -43.15%, while year-to-date (YTD) performance is -24.52%. ASXC stock has a five-year performance of %. Its 52-week range is between 0.2504 and 1.18, which gives ASXC stock a 52-week price range ratio of 1.25%
Asensus Surgical Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 0.98, a price-to-sale (PS) ratio of 23.22, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -49.38%, a ROC of -48.50% and a ROE of -55.15%. The company’s profit margin is -%, its EBITDA margin is -832.80%, and its revenue ttm is $4.62 Million , which makes it $0.02 revenue per share.
Of the last four earnings reports from Asensus Surgical Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.07 for the next earnings report. Asensus Surgical Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for Asensus Surgical Inc. is Strong Buy (1), with a target price of $2.25, which is +758.78% compared to the current price. The earnings rating for Asensus Surgical Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Asensus Surgical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Asensus Surgical Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.02, ATR14 : 0.03, CCI20 : -100.21, Chaikin Money Flow : -0.12, MACD : -0.02, Money Flow Index : 37.25, ROC : -9.83, RSI : 39.90, STOCH (14,3) : 12.39, STOCH RSI : 0.39, UO : 33.20, Williams %R : -87.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Asensus Surgical Inc. in the last 12-months were: Andrea Biffi (Buy at a value of $207 557), Anthony C. J. Fernando (Option Excercise at a value of $0), Anthony Fernando (Option Excercise at a value of $0), Rampertab Shameze (Option Excercise at a value of $0), Shameze Rampertab (Option Excercise at a value of $0)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Asensus Surgical Inc is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy, and addresses the current clinical, cognitive, economic shortcomings in surgery. The Senhance Surgical System features as the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. Its segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.
CEO: Anthony C. J. Fernando
Telephone: +1 919 765-8400
Address: 1 TW Alexander Drive, Durham 27703, NC, US
Number of employees: 138
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.